Fischbach M, et al. - In this study, researchers attempted to assess the efficacy and long-term safety of continuous erythropoietin receptor activator–methoxy polyethylene glycol-epoetin beta (C.E.R.A.) in pediatric patients with anemia of CKD undergoing hemodialysis, as well as, to identify a conversion factor for switching from previous erythropoiesis-stimulating agents (ESAs) to C.E.R.A. Four-weekly C.E.R.A. was found to be efficacious in maintaining hemoglobin levels in this patient population with stable anemia of CKD, switching from maintenance treatment with epoetin alfa/beta or darbepoetin, when a defined conversion factor was used. Additionally, data revealed that safety was consistent with the known C.E.R.A. safety profile in adults.